Rimegepant: A New Hope for Preventing Episodic Migraines

Research Summary

A recent study published in the journal Cephalalgia explored the effectiveness of rimegepant in preventing episodic migraines for adults who had previously experienced inadequate responses to traditional oral preventive medications. This phase 4, multinational trial involved 652 participants and included an untreated 28-day period followed by a 12-week treatment phase. Participants were randomly assigned to receive either rimegepant, a 75 mg orally disintegrating tablet, or a placebo. Results showed that rimegepant significantly reduced monthly migraine days compared to placebo, with a difference of 1.6 days. All secondary endpoints favored rimegepant, including improvements in quality of life and reduced migraine severity. Rimegepant was well tolerated, showing no significant difference in safety compared to placebo. This study highlights rimegepant as an effective preventive treatment for those struggling with traditional migraine medications.

Study Details

📄 Title: A phase 4, randomized, double-blind, placebo-controlled trial evaluating the efficacy and tolerability of rimegepant for the prevention of episodic migraine in adults with a history of inadequate response to traditional oral preventive medications.

👥 Research Team: Pozo-Rosich P et al.

📚 Published In: Cephalalgia

📅 Publication Date: 2025 Nov

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.